GLP-1 agonists

Background

  • Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
  • Released by L-cells of the small intestinge in response to the presence of nutrients
  • Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
  • Slows gastric emptying times
  • Increases satiety, which decreases drive for food intake

Types

Short Acting Dose
Exenatide(Byetta) 5-10 mcg SC bid
Liraglutide(Victoza) 0.6-1.8 mg SC daily
Long Acting
Exenatide(Bydureon) 2 mg SC qwk
Albiglutide(Tanzeum) 30-50 mg SC qwk
Dulaglutide(Trulicity) 0.75-1.5 mg qwk

Indication

  • Diabetes Mellitus, Type 2

Adverse Reactions

  • Nausea, vomiting, diarrhea
  • Acute pancreatitis
  • Exenatide should not be used in patients with creatinine clearance below 30mL/min
  • Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B

See Also

Diabetes medications

References

1.Epocrates

2.http://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?source=see_link&sectionName=GLUCAGON-LIKE+PEPTIDE-1&anchor=H2#H619400